文献速递淋巴瘤

静脉大剂量甲氨蝶呤为主全身治疗孤立性原发性玻璃体视网膜淋巴瘤:LOC网络研究

Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study.
PubMed 文献 · Am J Hematol · 2021-05-03

该法国多中心回顾性研究纳入59例初诊孤立性原发性玻璃体视网膜淋巴瘤(PVRL)患者,一线接受静脉大剂量甲氨蝶呤(IV HD-MTX)为主的全身治疗。中位随访61个月,中位总生存75个月,42例(71%)复发,其中29例首次复发为孤立眼部复发,共22例脑复发。该方案可行性好、毒性可接受,可预防脑复发并延长总生存,但眼部复发率仍高。

要点

  • IV HD-MTX为主一线治疗孤立性PVRL可行性好,毒性可接受,老年人群亦适用。
  • 中位随访61个月,42/59(71%)复发,29例首次复发为孤立眼部复发,共22例脑复发。
  • 中位总生存75个月,无进展生存18个月,眼部无复发生存29个月,脑无复发生存73个月。

核心结论

  • IV HD-MTX为主的全身治疗作为孤立性PVRL一线治疗可行、毒性可接受,可预防脑复发并延长总生存,但眼部复发率仍高。

研究设计与样本

  • 法国全国数据库回顾性研究,纳入2011至2018年间初诊孤立性PVRL并一线接受HD-MTX治疗的患者59例,中位年龄70岁,中位KPS 90%。

主要发现

  • 8/59例同时接受局部治疗;未报告因毒性导致的死亡或MTX提前终止。
  • 化疗后40/57例获完全缓解;治疗前89%患者房水或玻璃体IL-10升高。
  • 治疗后CR/uCR/PR患者中87%房水IL-10不可测,PD/SD患者中92%可测。
  • 中位随访61个月,42/59(71%)复发,29例首次复发为孤立眼部复发,共22例脑复发。
  • 中位总生存75个月,无进展生存18个月,眼部无复发生存29个月,脑无复发生存73个月。

临床怎么用

  • IV HD-MTX为主全身治疗可作为孤立性PVRL一线选择,尤其适用于老年患者。
  • 眼部评估可结合房水IL-10监测,治疗后IL-10不可测与缓解相关。

局限性

  • 回顾性研究设计,样本量59例,部分患者联合局部治疗,结果需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of primary vitreoretinal lymphoma (PVRL) remains controversial regarding the use of local, systemic, or combined treatments. The aim of this study was to analyze the efficacy and toxicity of intravenous high-dose methotrexate (IV HD-MTX) based systemic therapy in a uniformly treated population of PVRL patients. From a nationwide French database, we retrospectively selected 59 patients (median age: 70 years, median Karnofsky Performance Status: 90%) with isolated PVRL at diagnosis who received first-line treatment with HD-MTX between 2011 and 2018. 8/59 patients also received a local treatment. No deaths or premature discontinuations of MTX due to toxicity were reported. A complete response was obtained in 40/57 patients after chemotherapy. Before treatment, IL-10 was elevated in the aqueous humor (AH) or in the vitreous in 89% of patients. After treatment, AH IL-10 was undetectable in 87% of patients with a CR/uCR/PR and detectable in 92% of patients with PD/SD. After a median follow-up of 61 months, 42/59 (71%) patients had relapsed, including 29 isolated ocular relapses as the first relapse and a total of 22 brain relapses. The median overall survival, progression-free survival, ocular-free survival and brain-free survival were 75, 18, 29 and 73 months, respectively. IV HD-MTX based systemic therapy as a first-line treatment for isolated PVRL is feasible, with acceptable toxicity, even in an elderly population. This strategy seems efficient to prevent brain relapse with prolonged overall survival. However, the ocular relapse rate remains high. New approaches are needed to improve local control of this disease, and ocular assessment could be completed by monitoring AH IL-10.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lam M, Touitou V, Choquet S, et al. Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study. Am J Hematol. 2021. PMID: 33864703. doi:10.1002/ajh.26199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。